4.7 Review

Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases

期刊

DRUG DISCOVERY TODAY
卷 15, 期 15-16, 页码 622-629

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2010.06.011

关键词

-

资金

  1. NHLBI NIH HHS [R01 HL052233, R01 HL080187, P01 HL048743, R01 HL070274] Funding Source: Medline
  2. NIDDK NIH HHS [R01 DK062729, R01 DK085006] Funding Source: Medline
  3. NINDS NIH HHS [R01 NS070001, P01 NS010828] Funding Source: Medline

向作者/读者索取更多资源

The Rho/rho-kinase (ROCK) pathway has an important role in the pathogenesis of several cardiovascular diseases. The activation of ROCK is involved in the regulation of vascular tone, endothelial dysfunction, inflammation and remodeling. The inhibition of ROCK has a beneficial effect in a variety of cardiovascular disorders. Evidence from animal models and from clinical use of ROCK inhibitors, such as Y-27632, fasudil and statins (i.e. pleiotropic effects), supports the hypothesis that ROCK is a potential therapeutic target. This review provides a current understanding of the role of ROCK pathway in the regulation of vascular function and the use of ROCK inhibitors in the treatment of cardiovascular disorders.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据